BridgeBio Pharma, Inc.
BBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $5,105,925 | $6,571,893 | $1,123,745 | $2,407,868 |
| - Cash | $681,101 | $375,935 | $376,689 | $393,772 |
| + Debt | $1,730,584 | $1,739,838 | $1,723,564 | $1,726,171 |
| Enterprise Value | $6,155,408 | $7,935,796 | $2,470,620 | $3,740,267 |
| Revenue | $221,902 | $9,303 | $77,648 | $69,716 |
| % Growth | 2,285.3% | -88% | 11.4% | – |
| Gross Profit | $218,024 | $6,857 | $74,214 | $66,602 |
| % Margin | 98.3% | 73.7% | 95.6% | 95.5% |
| EBITDA | -$436,829 | -$565,468 | -$397,443 | -$533,833 |
| % Margin | -196.9% | -6,078.3% | -511.9% | -765.7% |
| Net Income | -$535,762 | -$643,202 | -$481,183 | -$562,539 |
| % Margin | -241.4% | -6,913.9% | -619.7% | -806.9% |
| EPS Diluted | -2.88 | -3.95 | -3.35 | -4.43 |
| % Growth | 27.1% | -17.9% | 24.4% | – |
| Operating Cash Flow | -$520,726 | -$527,720 | -$419,494 | -$497,934 |
| Capital Expenditures | -$933 | -$1,306 | -$6,321 | -$48,246 |
| Free Cash Flow | -$521,659 | -$529,026 | -$425,815 | -$546,180 |